Other Routes of Protein and Peptide Delivery: Transdermal, Topical, Uterine, and Rectal - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 662

[126] Lin WW, Pulkkinen MT, Vitto L, Yoon KJ. The gene gun: current applications in cuta-
neous gene therapy. Int J Dermatol 2000;39:161-70.
[127] Lee W, Pan T, Wang P, Zhuo R, Huang C, Fang J-Y. Erbium: YAG laser enhanced trans-
dermal peptide delivery and skin vaccination. J Control Release 2008;128:200-8.
[128] Lenz GR, Mansson PE. Growth factors as pharmaceuticals. Pharm Technol 1991;15:
34-40.
[129] Papanas N, Maltezos E. Growth factors in the treatment of diabetic foot ulcers: new
technologies, any promises? Int J Low Extrem Wounds 2007;6:37-53.
[130] Celebi N, Erden N, Gonul B, Koz M. Effects of epidermal growth factor dosage forms
on dermal wound strength in mice. J Pharm Pharmacol 1994;46:386-7.
[131] Okumura K, Kiyohara Y, Komada F, Iwakawa S, Hirai M, Fuwa T. Improvement in
wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat,
gabexate, or gelatin on stabilization and efficacy of EGF. Pharm Res 1990;7:1289-93.
[132] Kiyohara Y, Komada F, Iwakawa S, Fuwa T, Okumura K. Systemic effects of epidermal
growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns
or open wounds. Biol Pharm Bull 1993;16:73-6.
[133] Matuszewska B, Keogan M, Fisher DM, Soper KA, Hoe C, Huber AC, et al. Acidic
fibroblast growth factor: evaluation of topical formulations in a diabetic mouse wound
healing model. Pharm Res 1994;11:65-71.
[134] Hsu CC, Nguyen HM, Wu SS. Reconstitutable lyophilized protein formulation. US
Patent, 5,192,743. 1993. March 9.
[135] Mezei M, Gulasekharam V. Liposomes—a selective drug delivery system for the topical
route of administration: gel dosage form. J Pharm Pharmacol 1982;34:473-4.
[136] Ganesan MG, Weiner ND, Flynn GL, Ho NFH. Influence of liposomal drug entrapment
on percutaneous absorption. Int J Pharm 1984;20:139-54.
[137] Mezei M. Liposomes as a skin drug delivery system. In: Breimer DD, Speiser P,
editors. Topics in pharmaceutical sciences. Amsterdam: Elsevier Science Publishers;
1985. p. 345-58.
[138] Martin GP. Phospholipids as skin penetration enhancers. In: Walters KA, Hadgraft J,
editors. Pharmaceutical skin penetration enhancement. New York, NY: Marcel Dekker;
1993. p. 57-60.
[139] Duplessis J, Ramachandran C, Weiner N, Muller DG. The influence of particle size of
liposomes on the deposition of drug into skin. Int J Pharm 1994;103:277-82.
[140] Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers dermal and
transdermal drug delivery. J Control Release 1994;30:1-15.
[141] Siciliano AA. Topical liposomes—an update and review of uses and production meth-
ods. Cosmetics Toiletries 1985;100:43-6.
[142] Egbaria K, Ramachandran C, Kittayanond D, Weiner N. Topical delivery of liposo-
mally encapsulated interferon evaluated by in vitro diffusion studies. Antimicrob Agents
Chemother 1990;34:107-10.
[143] Bogner RH, Banga AK. Iontophoresis and phonophoresis. US Pharm 1994;19:H10-26.
[144] Golomb G, Avramoff A, Hoffman A. A new route of drug administration: intrauterine
administration of insulin and calcitonin for systemic effect. Pharm Res 1993;10:828-33.
[145] Hoffman A, Nyska A, Avramoff A, Golomb G. Continues versus pulsatile administration
of erythropoietin (EPO) via the uterus in anemic rats. Int J Pharm 1994;111:197-202.
[146] Katz DF, Dunmire EN. Cervical mucus—problems and opportunities for drug delivery
via the vagina and cervix. Adv Drug Deliv Rev 1993;11:385-401.
[147] Reardon PM, Gochoco CH, Audus KL, Wilson G, Smith PL. In vitro nasal transport
across ovine mucosa: effects of ammonium glycyrrhizinate on electrical properties and